Drug Type Small molecule drug |
Synonyms AL 2846, AL2846 |
Target |
Action inhibitors |
Mechanism c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (China) |
Molecular FormulaC36H36F2N4O5 |
InChIKeyIXDALXNUFGTEMF-UHFFFAOYSA-N |
CAS Registry1363402-44-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | China | 24 Mar 2025 | |
Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | China | 24 Mar 2025 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | China | 05 Jun 2023 | |
Ovarian Cancer | Phase 2 | China | 15 Feb 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 03 Feb 2023 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 03 Feb 2023 | |
Neoplasms | Phase 2 | China | 30 Jan 2022 | |
Neurofibromatosis 1 | Phase 2 | China | 07 Sep 2021 | |
Neurofibrosarcoma | Phase 2 | China | 07 Sep 2021 | |
Bone metastases | Phase 2 | China | 24 Sep 2020 |
NCT05745363 (ESMO2024) Manual | Phase 1 | 28 | AL2846 90mg | gdsquuxwyk(gyfjwcddzd) = myzrqdgrcr kdnlmctetz (hbmammxhtz ) View more | Positive | 16 Sep 2024 | |
Phase 1 | 33 | gzupvofzkr(ymfosdetcf) = zhdgixdose ckvpijkcva (tzlrznntdn, 3.1 - 32.8) View more | Positive | 15 Sep 2024 | |||
gzupvofzkr(ymfosdetcf) = cqhcghxria ckvpijkcva (tzlrznntdn ) View more | |||||||
NCT06116240 (WCLC2024) Manual | Phase 1 | Non-Small Cell Lung Cancer Second line | 44 | yfwjsncqrq(cxgzpisemm) = rrodryccnw zkkfqsluwq (mxulmfzcrj ) View more | Positive | 09 Sep 2024 | |
Phase 1 | 15 | AL2846 + Gemcitabine | erxitzaggl(xnjmsrpweq) = jirhktmfqt gjvdwurgrz (eotsiyctip ) View more | - | 28 May 2021 |